This study is being conducted at seven major children's hospitals in Australia and New Zealand to test a new approach for treating a virus, called cytomegalovirus in children with weakened immune systems. The researchers want to find out if using a web app to customise the dose of a medication called ganciclovir is better at clearing the virus over a six-week period compared to the standard method of giving the medication.
Immunocompromised patients including transplant recipients (haematopoietic stem cell transplant (HSCT), solid organ transplant (SOT)), those receiving chemotherapy or other immunosuppression or those with a known/suspected inborn error of immunity (determined by an immunologist); and
Detectable clinically significant CMV viraemia and treating clinician determines that antiviral therapy is indicated.
Willing to partake in the trial
Willing/able to attend all follow up visits and capable of completing all trial assessments.
Current or prior CMV infection with documented genotypic resistance to GCV (UL97 and/or UL54); or
Severe renal impairment (defined as estimated glomerular filtration rate (eGFR) <25mL/min); or
Congenital CMV infection; or
Life expectancy of less than 7 days as determined by the treating physician; or